The IRAK4 inhibitor emavusertib was tested in two marginal zone lymphoma models (VL51 and Karpas1718) [41,42] and their derivatives with secondary resistance to PI3K and BTK inhibitors [32,43,44,45]. This evidence concerns the gene IRAK4 and lymphoma.